PharmaShots | Incisive News in 3 Shots

Subscribe Now

Elevar Therapeutics

Elevar Therapeutics Entered into a License Agreement with Jiangsu Hengrui Pharma for Camrelizumab + Rivoceranib for Unresectable Hepatocellular Carcinoma

Elevar Therapeutics Entered into a License Agreement with Jiangsu Hengrui Pharma for Camrelizumab + Rivoceranib for Unresectable H...

October 19, 2023

Elevar Therapeutics Reports P-III Study (CARES 310) Results of Rivoceranib + Camrelizumab as a 1L Therapy for Unresectable Hepatocellular Carcinoma

Elevar Therapeutics Reports P-III Study (CARES 310) Results of Rivoceranib + Camrelizumab as a 1L Therapy for Unresectable Hepatoc...

July 25, 2023

Elevar Therapeutics Reports the US FDA Acceptance of NDA for Rivoceranib + Camrelizumab as 1L Treatment for Unresectable Hepatocellular Carcinoma

Elevar Therapeutics Reports the US FDA Acceptance of NDA for Rivoceranib + Camrelizumab as 1L Treatment for Unresectable Hepatocel...

July 18, 2023

PharmaShots Weekly Snapshot (March 23-27, 2020)

PharmaShots Weekly Snapshot (March 23-27, 2020)

March 30, 2020

Contact Us

First Floor, B-66, Sector 63 Noida, Uttar Pradesh, INDIA - 201301
+91-120 428 0707
connect@pharmashots.com
Newsletter

Our Information

Follow Us